Genmab CEO expects more legal twists in future

Danish biotech company Genmab is currently awaiting the verdict from an arbitration dispute with partner Johnson & Johnson. CEO at Genmab Jan van de Winkel sees an increased chance of more legal cases in the future, as the company continues to grow.

Photo: Tuala Hjarnø / Genmab / PR

As Genmab gets bigger on all parameters, so too increases the attention from lawyers and legal departments from competitors across the globe, says CEO of Genmab Jan van de Winkel, as reported by Danish business daily Børsen.

”Each case is different, but the reality is that as you become more successful you also find yourself legally challenged more often. I think we need to expect this will happen again in the future,” van de Winkel says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs